Balyasny Asset Management
CNTA

Balyasny Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Balyasny Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.9M Buy
852,828
+384,013
+82% +$9.82M 0.04% 488
2025
Q4 		$11.7M Sell
468,815
-336,796
-42% -$8.53M 0.01% 953
2025
Q3 		$19.5M Sell
805,611
-415,999
-34% -$7.39M 0.02% 729
2025
Q2 		$16.1M Buy
+1,221,610
New +$15.5M 0.02% 756
2025
Q1 		– Sell
-175,428
Closed -$2.94M – 2854
2024
Q4 		$2.94M Sell
175,428
-505,993
-74% -$8.38M ﹤0.01% 1520
2024
Q3 		$10.9M Sell
681,421
-341,701
-33% -$4.19M 0.02% 903
2024
Q2 		$9.24M Buy
1,023,122
+768,676
+302% +$7.29M 0.02% 920
2024
Q1 		$2.88M Buy
+254,446
New +$2.41M 0.01% 1424

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Balyasny Asset Management's CNTA Position: Q1 2026 in Review

Balyasny Asset Management increased its Centessa Pharmaceuticals (CNTA) stake by 82% in Q1 2026, buying an estimated $9.82M and bringing the position to 852,828 shares worth $33.9M. The position accounts for 0.04% of the portfolio, ranked #488.

Balyasny Asset Management first reported a position in CNTA in Q1 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Balyasny Asset Management held 852,828 shares of Centessa Pharmaceuticals worth $33.9M as of Q1 2026.
  • Balyasny Asset Management bought 384,013 Centessa Pharmaceuticals shares in Q1 2026, an estimated $9.82M.
  • Centessa Pharmaceuticals made up 0.04% of Balyasny Asset Management's portfolio in Q1 2026, its #488 holding.
  • Balyasny Asset Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.